Obesity Management 2016

Click "Begin" to evaluate sessions, claim CME & Maintenance of Certification (MOC) points, and print a certificate of attendance or certificate of participation

In order to earn and report MOC points to the American Board of Internal Medicine (ABIM), you must:

  1. Provide your board-certification information in your educational profile
  2. Evaluate the MOC sessions you attended through this form

Review & Edit your Profile

Target Audience

This program should be of substantial interest to: endocrinologists and endocrine fellows, primary care and internal medicine physicians, physician’s assistants, nurse practitioners and other healthcare professionals treating overweight and obese individuals.

Learning Objectives

Upon completion of this educational activity, learners will be able to:

Mechanisms Underlying Weight Loss With Bariatric Surgery: Lessons from Animal Models

  • Describe the role of hormonal and neural mechanisms in the regulation of appetite, food intake, and body weight

What’s the Best Diet for Weight Loss?

  • Describe the role of hormonal and neural mechanisms in the regulation of appetite, food intake, and body weight
  • Recognize the behavioral approaches to obesity management that are most impactful in practice

How to Use Commercial Weight Loss Programs to Treat Obesity in Private Practice

  • Develop an approach to choosing a treatment strategy that is most optimal for managing obesity
  • Discuss the usefulness of lifestyle and behavioral changes to reduce weight

Weight Bias: Implications for Clinical Practice

  • Describe the effects of weight bias
  • Develop intervention strategies to reduce weight bias in the clinical setting

Evidence-Based Pharmacotherapy for Obesity                  

  • Describe the mechanism of action, safety, and efficacy of new medical therapies for obesity
  • Discuss the clinical data on new pharmaceutical treatment options for obesity
  • Describe the weight consequences of certain pharmacologic therapies for obesity

Update on Weight Loss Surgery

  • Explain the comparative effectiveness of the surgical treatments for obesity, including what is known about mechanisms of action

New Weight Loss “Devices”

  • Explain the differences between the various devices
  • Discuss the pros and cons of each device in the clinical setting

Cases for Pharmacotherapy

  • Explore how newly-approved and emerging weight- loss drugs may be appropriately integrated into a weight-loss program
  • Apply updated practice guidelines in a clinical setting
  • Manage OTC drugs with prescribed pharmacologic agents and their effect on weight loss efforts

Management of Diabetes and Hypoglycemia in the Post-Bariatric Surgery Patient

  • Select appropriate medical therapy options for the co-management of diabetes and obesity
  • Explain the role new agents have in assisting current therapeutic challenges
  • Evaluate clinical practice guidelines on diabetes and management of comorbidities and predict how these will evolve in light of new data and clinical experience

How Do I Get My Patients to Move?

  • Explain the methods available for promoting lasting behavior change 
  • Recognize the behavioral approaches to obesity management that are most impactful in practice
  • Describe the most common issues in behavior change

Obesity and Weight Gain in Pregnancy: Optimizing Maternal and Infant Outcomes

  • Counsel obese patients prior to and during pregnancy
  • Discuss the short and long-term risks associated with pregnancy and obesity
  • Describe the best prevention or treatment options available to women looking to conceive

How to Set Up an Obesity Clinic in Private Practice

  • Describe the processes and successes for setting up an obesity clinic

Peri-Operative Management of the Bariatric Surgery Patient

  • Discuss the diagnosis and management of common peri-operative issues in the bariatric surgery patient

Gut Hormones and Obesity: Etiology and Potential Drug Treatments

  • Explain the relation of gut microbiota in the risk of obesity and potential treatment pathway

Additional Information

Target Audience: 
Clinical researcher
Scientific researcher
Nurse/Nurse practitioner
Physician assistant
Allied health professional
Competency Area: 
Patient Care and Procedural Skills
Medical Knowledge
Interpersonal and Communication Skills
Topic Area: 
Diabetes and Glucose Metabolism
Lipid Disorders and Fatty Liver Diseases
Health Disparities
Pediatric Endocrinology
Level of Outcomes: 
Level 1 (Participation)
Level 2 (Satisfaction)
Level 3A (Learning: Declarative Knowledge (Knows))
Level 3B (Learning: Procedural Knowledge (Knows How))
Activity summary
Available credit: 
  • 6.75 ABIM MOC
  • 6.75 AMA PRA Category 1 Credits
  • 6.75 CME Certificate of Participation
Course opens: 
Course expires: 
Boston, MA
United States

Program Chairs

Richard Atkinson, Jr., MD; Virginia Commonwealth Univ
Daniel Bessesen, MD, Univ of Colorado Sch of Med
Marc Cornier, MD; Univ of Colorado Sch of Med
William T. Donahoo, MD; Kaiser Permanente Colorado/Univ of Colorado Sch of Med


Caroline Apovian, MD; Boston Univ
Louis Aronne, MD; Weill Cornell Med Coll
Linda Barbour, MD; Univ of Colorado Sch of Med
Steven Blair, PED; Univ of South Carolina, Arnold Sch of Public Health
Stacy Brethauer, MD; Cleveland Clin
David D'Alessio, MD; Duke Univ Med Ctr
Nikhil Dhurandhar, PhD; Texas Tech Univ
Gary Foster, PhD; Weight Watchers International
Jeffrey Mechanick, MD; Icahn Sch of Med at Mount Sinai
Mary-Elizabeth Patti, MD; Joslin Diabetes Ctr
Rebecca Puhl, PhD; Univ of Connecticut, Rudd Ctr for Food Policy & Obesity
Philip Schauer, MD; Cleveland Clin
Randy Seeley, PhD; Univ of Michigan Med Sch


The faculty, committee members, and staff who are in position to control the content of this activity are required to disclose to the Endocrine Society and to learners any relevant financial relationship(s) of the individual or spouse/partner that have occurred within the last 12 months with any commercial interest(s) whose products or services are related to the CME content. Financial relationships are defined by remuneration in any amount from the commercial interest(s) in the form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options, or ownership interest excluding diversified mutual funds); honoraria or other payments for participation in speakers' bureaus, advisory boards, or boards of directors; or other financial benefits. The intent of this disclosure is not to prevent CME planners with relevant financial relationships from planning or delivery of content, but rather to provide learners with information that allows them to make their own judgments of whether these financial relationships may have influenced the educational activity with regard to exposition or conclusion.

The Endocrine Society has reviewed all disclosures and resolved or managed all identified conflicts of interest, as applicable.

The faculty reported the following relevant financial relationship(s) during the content development process for this activity:

Caroline Apovian, MD: Advisory Group Member, Enteromedics, Gelesis, Novo Nordisk, Nutrisystem, Scientific Intake, Zafgen; Advisory Group Member & Investigator, Orexigen; Advisory Group Member & Speaker Bureau Member, Takeda; Consultant, Science Smart LLC; Investigator, Aspire Bariatrics, GI Dynamics, MYOS Coroporation

Louis Aronne, MD: Board Member, Jamieson Labs, MYOS Corporation; Researcher, Aspire Bariatrics, Eisai; Scientific Board Member, Gelesis, GI Dynamics, Jovia Health, Novo Nordisk, Pfizer, Zafgen

Daniel Bessesen, MDData Safety Monitoring Board, EnteroMedics Inc.

Steven Blair, PED: Medical/Scientific Advisory Board Member, Cancer Foundation for Life, Clarity Project, Sports Surgery Clinic-Dublin; Researcher, National Institutes of Health, Body Media, The Coca-Cola Company, General Mills, U.S. Department of Defense; Royalties, Human Kinetics

Nikhil Dhurandhar, PhD: Advisory Group Member, Novo Nordisk

Gary Foster, PhD: Chief Scientific Officer, Weight Watchers

Mary-Elizabeth Patti, MD: Collaborator, Xeris Pharmaceutical; Principal Investigator, AstraZeneca, Medimmune

Philip Schauer, MDPrincipal Investigator, Ethicon, Medtronic (Covidien), Pacira; Speaker, Ethicon

Randy Seeley, PhDAd Hoc Consultant, Boehringer Ingelheim, Daiichi Sankyo, Nestle, Novartis Pharmaceuticals, Takeda; Ad Hoc Consultant and Principal Investigator, Johnson & Johnson, Sanofi; Advisory Group Member and Principal Investigator, Novo Nordisk

The following faculty reported no relevant financial relationships: Linda Barbour, MD; Marc Cornier, MD; David D'Alessio, MD; William T. Donahoo, MD; Jeffrey Mechanick, MD; Rebecca Puhl, PhD

The Endocrine Society staff associated with the development of content for this activity reported no relevant financial relationships.

Available Credit

  • 6.75 ABIM MOC
  • 6.75 AMA PRA Category 1 Credits
  • 6.75 CME Certificate of Participation